In a report issued on October 26, Olivier Calvet from Kepler Capital maintained a Buy rating on Medios AG (MEDOF – Research Report), with a price target of EUR46.00.
According to TipRanks.com, Calvet is ranked #1373 out of 7706 analysts.
Currently, the analyst consensus on Medios AG is a Strong Buy with an average price target of $55.20, implying a 2353.3% upside from current levels. In a report released yesterday, Deutsche Bank also maintained a Buy rating on the stock with a EUR50.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Medios AG is a holding company, which engages in the provision of pharmaceutical drugs. It operates through the following segments: Provision of Medicinal Products, Patient-specific Therapies, and Services. The Provision of Medicinal Products segment focuses on specialty pharmaceuticals means it trades almost exclusively in expensive medicinal products for chronic and/or rare diseases. The Patient-specific Therapies segment include infusions constituted and produced on the basis of individual symptoms and individual parameters such as body weight and body surface. The Services segment consists of all other Group activities, including Medios Group holding activities. The company was founded in 1980 and is headquartered in Berlin, Germany.
Read More on MEDOF:
- Analysts Offer Insights on Consumer Goods Companies: Adidas (OtherADDYY), Compagnie Générale des Établissements Michelin (OtherMGDDF) and Emmi AG (OtherEMLZF)
- Analysts Have Conflicting Sentiments on These Technology Companies: Nokia (NOK) and Paragon ID SA (OtherPAGDF)
- Analysts’ Top Conglomerates Picks: ABB (ABB), Ferrovial (FRRVY)
- Oppenheimer Maintains Their Hold Rating on Flowserve (FLS)
- Edwards Lifesciences (EW) Receives a Hold from BTIG
